Jacob Moyer, BS

Jacob Moyer, BS, is a graduate researcher at Mayo Clinic.

Articles by Jacob Moyer, BS

Jacob Moyer, BS, graduate researcher, Mayo Clinic; Mark Tyson II, MD, MPH, urologic oncologist, associate professor, urology, Mayo Clinic Alix School of Medicine

Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH

ByJacob Moyer, BS,Mark D. Tyson, II, MD, MPH

May 1st 2025

Moyer on Early Efficacy Data With Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

ByJacob Moyer, BS

March 19th 2025

Jacob Moyer, BS, discusses early, real-world efficacy and safety data with nadofaragene firadenovec in BCG-unresponsive non–muscle-invasive bladder cancer.

Jacob Moyer, BS

Articles by Jacob Moyer, BS

Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH

Moyer on Early Efficacy Data With Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

Latest Updated Articles

Trending on OncLive

HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA

Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg

Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis

Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL

TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC